AztraZeneca and Pieris Pharmaceuticals collaborate on treatment for respiratory conditions

Gowling WLG's life sciences team has been instrumental in assisting longstanding client AstraZeneca on its collaboration with Pieris Pharmaceuticals.

This new partnership will accelerate the development and commercialisation of a new inhale treatment for respiratory diseases. This key and innovative collaboration benefits not only the clients themselves, but enhances the development of a new type of treatment for these conditions and may have significant benefits for patients.

The Life Sciences team was led by partner Patrick Duxbury.

The agreement will see Pieris receive upfront and near-term milestone payments. The company also has the potential to receive development-dependent milestones and commercial payments for the products, as well as tiered royalties.